Congress Clarifies Rescheduling Impact as Cannabis Reform Stalls

A new congressional report provides the most detailed federal analysis to date on the practical implications of moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. The document outlines how rescheduling would maintain federal prohibition while creating narrow exemptions for FDA-approved medications, leaving most industry operations in regulatory limbo.

The report confirms that rescheduling alone would not legalize recreational or medical cannabis programs currently operating in 38 states. Federal agencies would retain enforcement authority over cultivation, distribution, and retail operations that lack specific FDA approval. This regulatory framework creates continued uncertainty for publicly traded operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF), which have built multi-billion dollar valuations on state-legal operations.

Investors have closely watched rescheduling developments as a potential catalyst for sector-wide revaluation, particularly regarding 280E tax relief and banking access. The congressional analysis indicates that while Schedule III classification could provide some tax benefits, it would not resolve fundamental banking restrictions or interstate commerce barriers that currently fragment the $30 billion U.S. cannabis market into state-by-state silos.

The timing of this report coincides with growing political momentum for comprehensive reform legislation rather than administrative rescheduling. Senate Banking Committee hearings have highlighted how piecemeal regulatory changes fail to address systemic issues facing cannabis businesses, from capital access restrictions to operational compliance costs that can exceed 15% of gross revenue.

For cannabis equity markets, the congressional findings reinforce the view that meaningful sector catalysts require legislative action beyond DEA scheduling changes. Multi-state operators continue trading at significant discounts to traditional consumer goods companies, with enterprise values averaging 2-3x revenue compared to 4-6x for comparable retail chains. Until federal frameworks align with state-legal operations, institutional investment remains constrained by regulatory uncertainty that rescheduling alone cannot resolve.